NASDAQ$ORGO

Organogenesis Holdings Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported a strong start to 2021 with significant revenue growth and improved profitability.

Organogenesis Holdings Inc. reported a strong first quarter in 2021, with net revenue increasing by 66% to $102.6 million compared to the first quarter of 2020. The company also saw a significant increase in net income, reporting $9.9 million compared to a net loss of $16.3 million in the same period last year.

  • Net revenue increased by 66% to $102.6 million compared to Q1 2020.
  • Advanced Wound Care products revenue increased by 77% compared to Q1 2020.
  • Surgical & Sports Medicine products revenue increased by 13% compared to Q1 2020.
  • Net income was $9.9 million, a significant improvement from the net loss of $16.3 million in Q1 2020.

Headline financials

Total Revenue

$103M

Previous: $61.7M+66.1%
EPS (adj)

$0.07

Previous: -$0.16+143.8%
Capital Expenditures

-$4.96M

Previous: -$4.24M-16.8%
Free Cash Flow

$4.99M

Previous: -$20.6M+124.3%
Net Income

$9.94M

Previous: -$16.3M+161.0%
Operating Income

$12.6M

Previous: -$15.1M+183.6%
Gross Profit

$77.1M

Previous: $42.9M+79.5%
Cash & Equivalents

$77.5M

Previous: $46.9M+65.2%
Total Assets

$319M

Previous: $208M+53.2%
Stock-Based Comp

$698K

Previous: $209K+234.0%

Revenue & EPS history

Organogenesis · Revenue · Quarterly

$103M

Q1 2021+66.1%vs Q1 2020
Beat estimate in 7 of 12 quarters(58%)
ActualEstimate

Revenue by segment

Organogenesis · $103M total across 2 segments · Q1 2021

  • Advanced Wound Care
    $90.7M+76.8%
  • Surgical & Sports Medicine
    $11.8M+13.4%

Forward guidance

For the twelve months ended December 31, 2021, the Company now expects net revenue of between $438 million and $454 million and GAAP net income and Adjusted EBITDA positive.

Tailwinds

  • Net revenue of between $438 million and $454 million, representing an increase of approximately 29% to 34% year-over-year
  • Net revenue from Advanced Wound Care products of between $409 million and $422 million, representing an increase of approximately 39% to 43% year-over-year
  • Net revenue from the sale of PuraPly products of between $179 million and $187 million, representing an increase of approximately 22% to 27% year-over-year
  • GAAP net income positive
  • Adjusted EBITDA positive

Headwinds

  • Net revenue from Surgical & Sports Medicine products of between $29 million and $32 million, representing a decrease of approximately 27% to 34% year-over-year

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+2.8%

Avg return

Earnings day

+3.2%

Avg return

5 days after

+0.5%

Avg return

30 days after

47%

17 / 36 earnings

Positive

+102.3%

Q4 2024

Best reaction

-42.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-6.2%-5.9%
Q4 2025-13.8%-22.4%-38.1%
Q3 2025+44.1%+66.6%+21.9%
Q1 2025-42.4%-43.6%-43.3%
Q4 2024+102.3%+95.8%+46.6%
Q3 2024+26.6%+10.3%+0.9%
Q2 2024+2.0%+6.4%-1.2%
Q1 2024+31.2%+23.2%+19.0%
Q4 2023-16.3%-20.3%-18.6%
Q3 2023+6.8%+22.9%+62.4%
Q2 2023-25.7%-27.0%-31.6%
Q1 2023+29.7%+43.2%+81.1%
Q4 2022+11.0%-2.9%-13.1%
Q3 2022-18.3%-11.5%-17.7%
Q2 2022-25.2%-26.6%-44.0%
Q1 2022+4.6%+9.8%-9.3%
Q4 2021+18.1%+15.6%+2.4%
Q3 2021-6.4%-5.0%-16.1%
Q2 2021+1.9%+2.5%+8.2%
Q1 2021-15.3%-11.3%-28.7%
Q4 2020+3.8%+8.5%+31.4%
Q3 2020+8.2%+5.2%+20.2%
Q2 2020+0.7%+1.5%+3.2%
Q1 2020-9.9%-18.8%+4.2%
Q4 2019-16.2%+11.6%+23.5%
Q3 2019+10.3%+8.8%-36.1%
Q2 2019-4.7%-10.8%+26.5%
Q1 2019-0.4%+1.0%+0.7%
Q4 2018-3.0%-5.3%-16.8%
Q4 2017-3.0%-5.3%-16.8%
Q2 2018+0.3%+0.2%+0.1%
Q1 2018+0.0%+0.4%+0.3%
Q3 2017+0.1%+0.1%-1.0%
Q2 2017+0.0%+0.1%+1.5%
Q1 2017-0.3%-0.3%+0.5%
Q4 2016+0.0%+0.0%+0.0%
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro